In breast cancers with amplification of the ErbB2 oncogene, which occurs in nearly 30% of breast cancer cases, receptor tyrosine kinase (RTK) inhibitors targeting epidermal growth factor receptors (EGFRs), like trastuzumab and lapatinib, have demonstrated significant clinical benefits as well3, 4. This evidence concerns the gene ERBB2 and breast carcinoma.